2. Signaling Pathways
  3. Anti-infection
  4. HIV

HIV

Human immunodeficiency virus

HIV

Related Products

PDF 1.67 MB

HIV (Human immunodeficiency virus) is a lentivirus (a subgroup of retrovirus) that causes the acquired immunodeficiency syndrome (AIDS), a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Infection with HIV occurs by the transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk. Within these bodily fluids, HIV is present as both free virus particles and virus within infected immune cells. HIV infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages, and dendritic cells. HIV infection leads to low levels of CD4+ T cells through a number of mechanisms, including apoptosis of uninfected bystander cells, direct viral killing of infected cells, and killing of infected CD4+ T cells by CD8 cytotoxic lymphocytes that recognize infected cells. When CD4+ T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections.

HIV Isoform Specific Products:

HIV Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-163851
    PROTAC Vif degrader-1
    		Inhibitor
    PROTAC Vif degrader-1 (Compound L15) is a Vif PROTAC degrader. PROTAC Vif degrader-1 has antiviral activity against HIV-1 (EC50: 33.35 μM against HIV-1IIIB). Blue: CRBN ligand (HY-10984); Black: linker; Pink: HIV-1 inhibitor(HY-163852).
    PROTAC Vif degrader-1
  • HY-163463
    PTP1B-IN-25
    		Inhibitor
    PTP1B-IN-25 (Compound 19) is a PTP1B inhibitor with remarkable antiviral, antibacterial, and antidiabetic activities. PTP1B-IN-25 has IC50 values of 0.37 μM, 8.6 μM, 3.7 μM, and 29 μM against PTP1B, HIV, α-Glucosidase, and methicillin-resistant Staphylococcus aureus (MRSA) respectively.
    PTP1B-IN-25
  • HY-15380
    PNU‐142721
    		Inhibitor
    PNU-142721 is a reverse transcriptase inhibitor and PXR agonist that effectively inhibits various type I HIV variants.
    PNU‐142721
  • HY-137697
    ddCTP
    		Inhibitor
    ddCTP is a type of chain-terminating deoxynucleotide. ddCTP can be incorporated into the extension primer chain that lacks the 3'-hydroxyl group, thereby terminating primer extension, viral genome replication, and DNA synthesis. ddCTP can distinguish almost identical RNA through distinguishable extension products in primer extension inhibition experiments. ddCTP is the active metabolite of Zalcitabine (HY-17392), which can competitively inhibit HIV reverse transcriptase, terminate the synthesis of viral DNA chains, and thereby inhibit HIV replication.
    ddCTP
  • HY-174269
    HIV Capsid-IN-2
    		Inhibitor
    HIV Capsid-IN-2 (Compound IC-2b4) is a potent HIV-1 capsid protein (CA) inhibitor. HIV Capsid-IN-2 shows inhibitory effects against both HIV-1 (EC50=0.08 μM) and HIV-2. HIV Capsid-IN-2 exerts inhibitory effects during both early and late stages of infection by directly and stably binding to HIV-1 CA.
    HIV Capsid-IN-2
  • HY-151938
    Reverse transcriptase-IN-3
    		Inhibitor
    Reverse transcriptase-IN-3 is a pyrimidine-5-carboxamide derivative, acts as an inhibitor of HIV-1. Reverse transcriptase-IN-3 shows potent activity against the HIV-1 wild-type and mutant strains.
    Reverse transcriptase-IN-3
  • HY-B1122R
    L-Cycloserine (Standard)
    		Inhibitor
    L-Cycloserine (Standard) is the analytical standard of L-Cycloserine. This product is intended for research and analytical applications. L-Cycloserine ((S)-4-Amino-3-isoxazolidone) is an oral inhibitor of the enzyme gamma-aminobutyric acid (GABA) transaminase (GABA-t) and branched-chain transaminases in Mycobacterium tuberculosis. L-Cycloserine has anticonvulsant properties and inhibits the synthesis of neurotensin in mouse brains[1][2][3][4].
    L-Cycloserine (Standard)
  • HY-177098
    Lepetegravir
    		Inhibitor
    Lepetegravir (Example 24) is a HIV integrase inhibitor. Lepetegravir has antiviral effects (EC50: 0.98 nM in MT-4 cells).
    Lepetegravir
  • HY-163161
    HIV-1 inhibitor-62
    		Inhibitor
    HIV-1 inhibitor-62 (compound 6) is an HIV-1 inhibitor that can be used in antiviral research.
    HIV-1 inhibitor-62
  • HY-P10834
    NYAD-13
    		Inhibitor
    NYAD-13 exhibits antiviral activity against HIV-1 IIIB, but it also possesses significant cytotoxicity.
    NYAD-13
  • HY-N7330
    Integracin B
    		Inhibitor
    Integracin B is a potent dimeric alkyl aromatic inhibitor of HIV-1 integrase discovered from the screening of fungal extracts using an in vitro assay. Integracin B inhibits both coupled and strand transfer activity of HIV-1 integrase.
    Integracin B
  • HY-177639B
    Lefelsiran sodium scrambled negative control
    		Inhibitor
    Lefelsiran sodium scrambled negative control is the sequence scrambled negative control of Lefelsiran sodium.
    Lefelsiran sodium scrambled negative control
  • HY-P991428
    DIACC-1010
    		Inhibitor
    DIACC-1010 is a human monoclonal antibody (mAb) targeting PLA2G1B. DIACC-1010 can be used in HIV infections research.
    DIACC-1010
  • HY-N3318
    Marsdenoside F
    		Control
    Marsdenoside F is a polyoxygenated pregnane glycoside isolated from the stems of Marsdenia tenacissima. Marsdenoside F showed no significant cytotoxicity against A549 and MCF-7 cell lines, nor did it exhibit significant anti-HIV activity.
    Marsdenoside F
  • HY-146753
    HIV-1 inhibitor-20
    		Inhibitor
    HIV-1 inhibitor-20 is a potent HIV-1 inhibitor by non-classical isosteric replacement of amide to 1,2,4-oxadiazoles.
    HIV-1 inhibitor-20
  • HY-10585B
    Valproic acid sodium (2:1)
    		Inhibitor
    Valproic acid (VPA) sodium (2:1) is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium (2:1) activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
    Valproic acid sodium (2:1)
  • HY-178341
    NNRT-IN-13
    		Inhibitor
    NNRT-IN-13 is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor that directly inhibiting HIV-1 reverse transcriptase (IC₅₀ = 0.25 μM). NNRT-IN-13 exhibits excellent antiviral activity against wild-type HIV-1 (EC₅₀ = 0.0046 μM) and a broad spectrum of drug-resistant mutants. NNRT-IN-13 exhibits favorable in vivo metabolic and safety profiles. NNRT-IN-13 can be used for human immunodeficiency virus (HIV) research.
    NNRT-IN-13
  • HY-139631
    HIV-1 inhibitor-9
    		Inhibitor
    HIV-1 inhibitor-9 is found to be potent inhibitor against the wild-type (WT) HIV-1 strain or multiple NNRTI-resistant strains at low nanomolar levels.
    HIV-1 inhibitor-9
  • HY-177670B
    Zintevir sodium scrambled negative control
    		Inhibitor
    Zintevir sodium scrambled negative control is the sequence scrambled negative control of Zintevir sodium.
    Zintevir sodium scrambled negative control
  • HY-17427S2
    Emtricitabine-13C,15N2
    		Inhibitor
    Emtricitabine-13C,15N2 (BW1592-13C,15N2) is a 13C- and 15N-labeled Emtricitabine (HY-17427). Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC50 of 0.01 μM in PBMC cell. It is an antiviral agent for the treatment of HIV infection.
    Emtricitabine-<sup>13</sup>C,15</sup>N<sub>2</sub>
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
HIV Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.